Brain Scans Reveal a Hidden Alzheimer’s Window

Cortical thickness changes in cognitively healthy older adults were measurable at least seven years before amyloid plaques became visible on PET scans – the imaging technology currently treated as medicine’s earliest reliable window into Alzheimer’s disease. The finding was published in August 2026 in Nature Neuroscience by researchers at the University of Oslo’s Department of Psychology.

Amyloid-PET imaging, a scanning technique that lights up sticky protein deposits called amyloid plaques in the brain, has long been considered the most sensitive early marker available for Alzheimer’s disease. Identifying high amyloid burden on PET was treated as the starting point for the disease’s measurable biological progression. The Oslo study found that the gold standard for imaging in Alzheimer’s disease had not been sensitive enough to detect early brain processes associated with the disease – with structural changes detectable at least seven years before plaques became visible on PET.

James Michael Roe led the study as a postdoctoral researcher at the Centre for Lifespan Changes in Brain and Cognition (LCBC) at the Department of Psychology, University of Oslo. He now works as International Scientific Lead at Cercare Medical, a neuroimaging technology company headquartered in Aarhus, Denmark. The study’s co-investigators included researchers from institutions across Europe and North America, drawing on one of the field’s most extensive collections of longitudinal brain imaging data.

The Scale of the Problem

According to the Alzheimer’s Association’s 2026 Facts and Figures, an estimated 7.4 million Americans age 65 and older are living with Alzheimer’s in 2026. Alzheimer’s disease is the leading cause of dementia worldwide.

The mortality picture is equally serious. A 2026 study in Alzheimer’s and Dementia identified Alzheimer’s as the sixth-leading cause of death among Americans age 65 and older. Any credible extension of the detectable window carries real clinical and public health stakes.

What Amyloid-PET Actually Measures – and Where It Falls Short

Alzheimer’s disease is characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain – the signature pathological features used to define the disease’s biological presence.

Amyloid-PET works by introducing a radioactive tracer into the bloodstream that binds to amyloid deposits in the brain, making them visible on a scanner. BrightFocus Foundation notes that these scans allow accurate detection of amyloid plaques in living people.

The limitation is a matter of threshold. PET can only register amyloid deposits once they reach a certain concentration – a level defined as “amyloid positivity.” Below that threshold, the scan reads negative, and the clinical convention has been that the patient is not yet on the Alzheimer’s biological trajectory. The Oslo study challenges that convention directly, finding that PET had not been sensitive enough to detect early brain processes associated with the disease.

MRI, by contrast, provides structural rather than molecular information. Longitudinal MRI from the Oslo study revealed that the cortex becomes relatively thicker years before amyloid positivity is detected on PET – a counterintuitive thickening, rather than the thinning typically associated with neurodegeneration, that sits at the heart of the team’s discovery.

The Study: Two Decades of Watching Healthy Brains Change

Rather than comparing groups of people with and without Alzheimer’s at a single point in time, the team followed cognitively healthy older adults through repeated brain imaging sessions spanning close to two decades. This design gave them a continuous record of the same individuals’ brains during the years before any clinical or imaging alarm was raised.

As Professor Anders Martin Fjell, head of the LCBC, explained: “These are cognitively well-functioning older individuals. We have examined changes in brain structure in the years before the first scan revealed plaques.”

Because the researchers had scans spanning so many years, they could estimate when each participant’s amyloid first crossed the PET-detectable threshold and then look backward through their MRI history to see what was happening in the brain before that threshold was crossed. Structural changes, specifically in cortical thickness, were already detectable at least seven years before amyloid levels rose high enough to trigger a positive PET scan.

As Roe stated: “We found that structural changes in the brain occur many years before high levels of plaque are seen on PET scans, which is the brain scan currently used to identify the earliest signs of Alzheimer’s disease.”

The participants showing these early structural shifts were not impaired – they were thinking and functioning normally. The MRI changes preceded not just clinical symptoms, but also the imaging markers that until now defined the disease’s preclinical phase.

Cortical Thickness: The Unexpected Signal

In established Alzheimer’s disease, the cortex – the outer layer of the brain responsible for thinking, memory, and sensory processing – shrinks as neurons die. Earlier MRI-based detection efforts have therefore focused on finding early signs of thinning or atrophy.

The Oslo study found the opposite pattern in the pre-amyloid phase. Longitudinal MRI showed the cortex becoming relatively thicker years before amyloid positivity appeared on PET. This paradoxical thickening may represent inflammation, the swelling of glial support cells, or another compensatory biological process, though the study does not establish the mechanism definitively.

Two Competing Hypotheses: What Comes Before Amyloid?

The dominant model of Alzheimer’s disease pathology places amyloid accumulation at the beginning of the biological cascade, with structural brain changes and cognitive symptoms following later. If structural changes are visible before amyloid rises to detectable levels, the model needs revision.

Two explanations are plausible. The first is that amyloid is already accumulating, just below the sensitivity floor of current PET technology. In that scenario, the MRI changes are responding to a genuine early amyloid signal that the scanner simply cannot yet detect. More sensitive imaging tools or molecular blood tests might eventually bring this phase into view.

The second explanation is more disruptive. Some other biological process – unrelated to or at least not driven by amyloid – may be altering brain structure before significant plaque buildup begins. That process could eventually contribute to amyloid accumulation, or it could represent an independent pathway in Alzheimer’s pathology.

As Professor Fjell noted: “If the latter is true, it suggests it is important to continue developing drugs that target processes other than amyloid plaque accumulation. But we need more research on this.”

He also emphasized that Alzheimer’s disease is extremely difficult to treat, partly because it is so closely intertwined with aging and is likely triggered by multiple factors – a deep entanglement that may mean a single-target therapeutic approach will never be sufficient.

The Treatment Pipeline and Why Earlier Detection Matters

The Oslo study’s findings land in a treatment landscape already under pressure to expand beyond amyloid. The FDA-approved anti-amyloid therapies lecanemab (Leqembi) and donanemab (Kisunla), approved in 2023 and 2024 respectively, work by clearing amyloid from the brain in patients with early symptomatic disease. As a 2026 analysis in Alzheimer’s & Dementia noted, there are no approved disease-targeted therapies for preclinical Alzheimer’s – the stage before symptoms appear – which is precisely the window the Oslo study is trying to access.

If structural brain changes are occurring seven or more years before amyloid PET becomes positive, then the period during which the brain is already departing from a healthy trajectory is substantially longer than current diagnostic tools can capture. Brain cells lost to neurodegeneration cannot be recovered; intervening during an earlier, less damaged phase is theoretically more likely to preserve function. The Oslo study does not resolve how to intervene that early, but it sharpens the case for why finding that window matters.

Blood Biomarkers: A Parallel Track to Earlier Detection

The Oslo MRI findings are not the only front on which Alzheimer’s early detection is advancing. A parallel line of research focuses on blood-based biomarkers – molecules measurable from a simple blood draw that may signal pathological change before imaging can detect it.

In 2025, the FDA approved two blood tests for Alzheimer’s disease: one comparing the ratio of pTau217 to beta amyloid developed by Fujirebio, and a pTau181 plasma test developed by Roche. Both are substantially cheaper and less invasive than PET imaging, raising the prospect of routine Alzheimer’s screening in primary care settings.

A separate 2026 study in Nature Communications led by Hyun-Sik Yang, MD, an assistant professor of neurology at Harvard Medical School and associate member of the Broad Institute of MIT and Harvard, found that plasma pTau217 levels could predict amyloid PET progression and cognitive decline years before abnormalities appeared on brain scans.

The picture emerging from both lines of research points toward a layered, multimodal approach to Alzheimer’s detection: blood tests flagging biochemical risk, structural MRI identifying early morphological change, and PET reserved for confirming amyloid burden when earlier markers are positive.

Read More: Scientists Find an Earlier Warning Sign of Alzheimer’s Than Memory Loss

Limitations and What Comes Next

The Oslo study’s longitudinal depth is its primary scientific asset, but the research carries important caveats. The early structural changes were identified through group-level statistical analysis of repeated scans, not through a test that can be applied to an individual patient to predict their Alzheimer’s risk with clinical precision.

Normal aging independently changes brain structure, including cortical thickness. Distinguishing disease-related patterns from age-related variation at the individual level remains a methodological challenge the Oslo study does not resolve. Future work will need to determine whether the early MRI changes specifically predict who goes on to develop cognitive symptoms, or whether they predict only who eventually becomes amyloid-positive on PET.

The study also does not establish causation. A temporal association between early MRI changes and later amyloid accumulation is not the same as evidence that those changes cause, or are caused by, the earliest molecular stages of Alzheimer’s. Combining the imaging data with blood biomarkers, cerebrospinal fluid analysis, and genetic risk profiling in more diverse populations will be necessary to build a complete picture.

According to Practical Neurology, neuropathological features of Alzheimer’s begin 15 to 20 years before obvious cognitive symptoms – a timeline that places the Oslo study’s seven-year window closer to the disease’s intermediate phase than its biological origin point. The full pre-symptomatic period may be considerably longer, and the search for earlier markers continues.

What This Means for You

Structural brain changes detectable by MRI are visible at least seven years before amyloid plaques reach the threshold measurable by PET – the technology currently positioned as the field’s gold standard for Alzheimer’s early detection. Two conclusions follow directly: the current diagnostic framework may be underestimating the true length of Alzheimer’s preclinical phase, and therapeutic trials that enroll patients only after amyloid-PET positivity may be treating brains that have already undergone years of undetected change.

If biological processes independent of amyloid are already altering brain structure before plaques accumulate, then amyloid-only drug strategies are entering the story partway through. Expanding the treatment pipeline to target these earlier processes is the logical next step, though the nature of those processes remains to be established.

For individuals concerned about cognitive health, the near-term picture is more measured. The MRI findings from Oslo are a research-level discovery, not a new clinical test. The blood-based biomarker field is moving faster toward clinical application: the FDA cleared two blood-based Alzheimer’s tests in 2025. For anyone with a family history of Alzheimer’s or early cognitive concerns, asking a neurologist about plasma pTau217 testing is a more actionable step right now than seeking an MRI-based structural assessment. Cardiovascular risk management, regular exercise, adequate sleep, and sustained cognitive engagement all reduce dementia risk through mechanisms that operate well before any scan can detect a problem.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.

Read More: A Rare Alzheimer’s Mutation Just Revealed a Protein Fold Nobody Had Ever Seen